| Dr Beth Harvey Geneux, MD | |
|
8001 Youree Dr, Suite 600, Shreveport, LA 71115-2302 | |
| (318) 212-3890 | |
| (318) 212-3888 |
| Full Name | Dr Beth Harvey Geneux |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 18 Years |
| Location | 8001 Youree Dr, Shreveport, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225167463 | NPI | - | NPPES |
| 2138481 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 135093 (North Carolina) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 204056 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Lsu Health Shreveport-st Mary Medical Cent | Shreveport, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lsu Health Sciences Center Shreveport Faculty Group Practice | 4082902721 | 529 |
News Archive
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
Combining two or more drugs can be an effective treatment of diverse diseases, such as cancer. Yet, at the same time, the wrong drug combination can cause major side effects. Currently there is no systematic understanding of how different drugs influence each other. Thus, elucidating how two given drugs interact, and whether they have a beneficial effect, would mean a major step towards drug development to treat diseases more effectively in the future.
Antibiotics for acute rhinosinusitis are prescribed frequently- especially for younger adult patients and in primary care settings-despite recent consensus guidelines that discourage antibiotic use in mild cases, according to a study in the May 2013 issue of Otolaryngology-Head and Neck Surgery.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 8 days ago
| Entity Name | Wk Pierremont Ob-gyn Specialists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063453850 PECOS PAC ID: 9739188285 Enrollment ID: O20061211000108 |
News Archive
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
Combining two or more drugs can be an effective treatment of diverse diseases, such as cancer. Yet, at the same time, the wrong drug combination can cause major side effects. Currently there is no systematic understanding of how different drugs influence each other. Thus, elucidating how two given drugs interact, and whether they have a beneficial effect, would mean a major step towards drug development to treat diseases more effectively in the future.
Antibiotics for acute rhinosinusitis are prescribed frequently- especially for younger adult patients and in primary care settings-despite recent consensus guidelines that discourage antibiotic use in mild cases, according to a study in the May 2013 issue of Otolaryngology-Head and Neck Surgery.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 8 days ago
| Entity Name | Lsu Health Sciences Center Shreveport Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013374222 PECOS PAC ID: 4082902721 Enrollment ID: O20161012000307 |
News Archive
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
Combining two or more drugs can be an effective treatment of diverse diseases, such as cancer. Yet, at the same time, the wrong drug combination can cause major side effects. Currently there is no systematic understanding of how different drugs influence each other. Thus, elucidating how two given drugs interact, and whether they have a beneficial effect, would mean a major step towards drug development to treat diseases more effectively in the future.
Antibiotics for acute rhinosinusitis are prescribed frequently- especially for younger adult patients and in primary care settings-despite recent consensus guidelines that discourage antibiotic use in mild cases, according to a study in the May 2013 issue of Otolaryngology-Head and Neck Surgery.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Beth Harvey Geneux, MD 8001 Youree Dr, Suite 600, Shreveport, LA 71115-2302 Ph: (318) 212-3890 | Dr Beth Harvey Geneux, MD 8001 Youree Dr, Suite 600, Shreveport, LA 71115-2302 Ph: (318) 212-3890 |
News Archive
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
Combining two or more drugs can be an effective treatment of diverse diseases, such as cancer. Yet, at the same time, the wrong drug combination can cause major side effects. Currently there is no systematic understanding of how different drugs influence each other. Thus, elucidating how two given drugs interact, and whether they have a beneficial effect, would mean a major step towards drug development to treat diseases more effectively in the future.
Antibiotics for acute rhinosinusitis are prescribed frequently- especially for younger adult patients and in primary care settings-despite recent consensus guidelines that discourage antibiotic use in mild cases, according to a study in the May 2013 issue of Otolaryngology-Head and Neck Surgery.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 8 days ago
Sabrina Benefield Castle, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2510 W. Bert Kouns Industrial Loop, Shreveport, LA 71118 Phone: 318-212-5000 Fax: 903-553-7751 | |
Rodney Wise, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1501 Kings Hwy, Dept Of Ob/gyn, Shreveport, LA 71103 Phone: 318-675-8700 Fax: 318-675-8706 | |
James Barrow, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1501 Kings Hwy, Department Of Ob Gyn, Shreveport, LA 71103 Phone: 318-675-5000 | |
Melissa Fett Jordan, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3100 Fairfield Ave, Unit 10a, Shreveport, LA 71104 Phone: 318-201-3939 | |
Amanda Deadmond, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 9391 Ellerbe Rd Ste C, Shreveport, LA 71106 Phone: 318-408-0100 Fax: 601-202-4685 | |
Russell D Burlison, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1455 E Bert Kouns Loop, Shreveport, LA 71105 Phone: 318-798-4400 Fax: 318-798-4621 | |
Dr. Ricky Allen Paul, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 8001 Youree Dr Ste 600, Shreveport, LA 71115 Phone: 318-212-3890 Fax: 318-212-3888 |